WESTMINSTER, Colo., July 18 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that it will report 2007
second quarter financial results on Tuesday, August 7, 2007, before the
U.S. financial markets open.
Paul L. Berns, President and Chief Executive Officer, and other members
of Allos' senior management will provide a company update and discuss
results via web cast and conference call on Tuesday, August 7, 2007 at 8:30
AM ET. The web cast of this call will be available from the homepage and
the investors/media section of the Company's web site, http://www.allos.com, and
will be archived for 30 days. Alternatively, callers may participate in the
conference call by dialing 866-225-8729 (domestic) or 480-629-9564
(international). Web cast and telephone replays of the conference call will
be available approximately two hours after the completion of the call
through Friday, August 24, 2007. Callers can access the replay by dialing
303-406-7325 (domestic) or 800-590- 3030 (international). The passcode is
3761474.
About Allos Therapeutics
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in a
pivotal Phase 2 trial in patients with relapsed or refractory peripheral
T-cell lymphoma. The Company is also investigating PDX in patients with non
small cell lung cancer and a range of other lymphoma sub-types. The
Company's other product candidate is RH1, a targeted chemotherapeutic agent
for which the Company expects to initiate a Phase 1 study in patients with
advanced solid tumors in the second half of 2007. For additional
information, please visit the Company's website at http://www.allos.com.
Safe Harbor Statement
The 2007 second quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those that can be found in the "Risk Factors"
section of Allos' Form 10-K for the year ended December 31, 2006 and in
Allos' periodic reports on Form 10-Q and Form 8-K. Allos is providing the
information contained in the press release and conference call as of the
date of the release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future events or
otherwise. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in the press release or the
conference call. No forward- looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Derek Cole, Vice President, Investor
Relations, +1-720-540- 5367, dcole@allos.com, or Jennifer Neiman,
Senior Manager, Corporate Communications, +1-720-540-5227,
jneiman@allos.com, both of Allos Therapeutics, Inc.
|
